Abstract
Identifying preimmunization biological characteristics that promote an effective vaccine response offers opportunities for illuminating the critical immunological mechanisms that confer vaccine-induced protection, for developing adjuvant strategies, and for tailoring vaccination regimens to individuals or groups. In the context of malaria vaccine research, studying preimmunization correlates of protection can help address the need for a widely-effective malaria vaccine, which remains elusive. In this study, common preimmunization correlates of protection were identified using transcriptomic data from four independent, heterogeneous malaria vaccine trials in adults. Systems-based analyses showed that a moderately elevated inflammatory state prior to immunization was associated with protection against malaria challenge. Functional profiling of protection-associated genes revealed the importance of several inflammatory pathways, including TLR signaling. These findings, which echo previous studies that associated enhanced preimmunization inflammation with protection, illuminate common baseline characteristics that set the stage for an effective vaccine response across diverse malaria vaccine strategies in adults.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT01994525 NCT02132299 NCT01366534 NCT01218893
Funding Statement
This work was supported by National Institutes of Health grants U19AI128914 (to K.D.S.) and P41GM109824 (to J.D.A.) as well as Bill & Melinda Gates Foundation grant GHVAP NG-ID18-Stuart.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We did not conduct the trials but performed retrospective analysis with deidentified samples. However, the ethical statement and clintrials.gov identifiers are described here. The IMRAS trial (NCT01994525) was conducted at the Naval Medical Research Center (NMRC) Clinical Trials Center from 2014 to 2016; the CHMIs were conducted at the Walter Reed Army Institute of Research (WRAIR) secure insectary. The study protocol was reviewed and approved by the NMRC Institutional Review Board in compliance with all federal regulations governing the protection of human subjects. WRAIR holds a Federal-wide Assurance from the Office of Human Research Protections (OHRP) under the Department of Health and Human Services as does NMRC. NMRC also holds a Department of Defense/Department of the Navy Federal-wide Assurance for human subject protections. All key personnel were certified as having completed mandatory human subjects' protection curricula and training under the direction of the WRAIR Institutional Review Board or the NMRC Office of Research Administration (ORA) and Human Subjects Protections Branch (HSPB). All potential study subjects provided written, informed consent before screening and enrollment and had to pass an assessment of understanding. This study was conducted according to the Declaration of Helsinki as well as principles of Good Clinical Practices under the United States Food and Drug Administration Investigational New Drug (IND) application BB-15767. This trial was performed under an IND allowance by the Food and Drug Administration (FDA) and was registered on ClinicalTrials.gov (NCT01994525). The BSPZV1 trial (NCT02132299) was performed in accordance with Good Clinical Practices. The protocol was approved by institutional review boards (IRBs) of the IHI (Ref. No. IHI/IRB/No:02-2014), the National Institute for Medical Research Tanzania (NIMR/HQ/R.8a/Vol.IX/1691), the Ethikkommission Nordwest-und Zentralschweiz, Basel, Switzerland (reference number 261/13), and by the Tanzania Food and Drug Authority (Ref. No. TFDA 13/CTR/0003); registered at Clinical Trials.gov (NCT02132299); and conducted under U.S. FDA IND application. The MAL68 trial (NCT01366534) protocol was approved by the WRAIR Institutional Review Board and PATH-Malaria Vaccine Initiative's Western IRB. The trial was undertaken in accordance with the provisions of the International Conference on Harmonization and Good Clinical Practice guidelines. Written informed consent was obtained from each subject before study procedures were initiated. The CPS trial (NCT01218893) received approval by the Central Committee for Research Involving Human Subjects of the Netherlands (approval NL33904.091.10) and were registered at ClinicalTrials.gov (clinical trials registration: NCT01218893). The study team complied with the Declaration of Helsinki and good clinical practice, including monitoring of data. Volunteers enrolled in both studies provided written informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Updated funding statement.
Data Availability
Raw sequencing data for the MAL68 trial is publicly available through Sequence Read Archive BioProject PRJNA401870. Raw sequencing data for the CPS trial is publicly available at Sequence Read Archive BioProject PRJNA381264. Data for the IMRAS and BSPZV1 trials will be available through the ImmPort portal (immport.org).
